Abstract: The present invention has an object to provide damaged hair improving agents and damaged hair improving cosmetics containing the same, capable of providing excellent improving effects on damaged hair without using cumbersome work and an expensive special component and retaining the effects for an extended period of time. It was found that by using one or more selected from specific L-ascorbic acid derivatives and salts thereof, which had been conventionally used in cosmetics as useful components due to physiological activities such as a skin-whitening effect, as hair improving agents, and further containing these in a hair cosmetic and applying the hair cosmetic to damaged hair, improving effects such as increasing the hydrophobicity on the damaged hair surface and further enhancing the smoothness of hair were exhibited. Thus, the damaged hair improving agents and the damaged hair improving cosmetics containing the same effective on damaged hair have been provided.

Abstract: There is provided a gel composition that comprises a betaine-based emulsifier and can be suitably used as a thickener for cosmetic preparations and the like. A gel composition comprising a neutralized product of an alkyl-modified carboxyl group-containing polymer, which is a copolymer of monomers comprising 100 parts by mass of (meth)acrylic acid (a), 2.5 to 5 parts by mass of a (meth)acrylic acid alkyl ester (b) in which the alkyl group has 18 to 24 carbon atoms, and 0.1 part by mass or less of a compound (c) having two or more ethylenically unsaturated groups; and a betaine-based emulsifier.

Abstract: The invention relates to an adhesive composition having a main fraction of synthetic tackifying resin, and a fraction of at least one macromolecular component, characterised in that said at least one macromolecular component comprises a copolymer of at least two different monomers taken from the alpha olefins and ethylene, to give the composition for strip-free hair removal mechanical or adhesive properties.

Abstract: Compositions including polycarbodiimide and derivatives thereof together with at least one additional active selected from one or more a carboxylic acid compound chosen from fatty acids, their salts, and mixtures thereof, a polycarboxylic acid compound other than one that is chosen from fatty acids, their salts, and mixtures thereof, and a cationic polymer to enhance the quality of the keratinous substrates. The present invention relates to a cosmetic treatment and process for treating keratinous materials, in particular for hair-care and hair-styling, wherein the composition can include the polycarbodiimide and at least one additional active in amounts sufficient to impart hydrophobicity to keratinous substrates, including hair fibers, upon application thereto. The present invention, in particular, relates to a hair treatment composition and process for enhancing durable non-permanent shaping and curling of the hair, retention of shaping under humidity, and resistance to frizz.

Abstract: To provide a cosmetic which is environmentally friendly and is excellent in all of spreadability on application, adhesion, hand feeling properties and transparency. A cosmetic including aliphatic polyester-based resin particles, wherein the aliphatic polyester-based resin particles have a volume-average particle diameter of 2 to 30 ?m, and a ratio of particles having a particle diameter of less than 1 ?m is 15% by volume or less and a ratio of particles having a particle diameter of more than 30 ?m is 6% by volume or less, is provided.

Abstract: The present invention relates to a process for treating human keratin fibres such as the hair, which comprises: i) a step of applying to the human keratin fibres a composition comprising: —at least one plant wax: —at least 60% by weight of water relative to the total weight of the composition; ii) followed by a step of heating the keratin fibres by means of a heating appliance at a temperature ranging from 80° C. to 160° C., preferably from 110° C. to 50° C., more preferably from 120° C. to 150° C., which is moved along the fibres, iii) optionally followed by a step of rinsing the keratin fibres.

Abstract: The present invention discloses a human body cleaner and manufacturing method thereof. The human body cleaner comprises 1% wt˜60% wt of garlic extract, and 40% wt˜99% wt of cleaning agent. The method for manufacturing the human body cleaner comprises the following steps: preparing a plurality of garlics, adding water in a predetermined ratio to a plurality of garlics to obtain a garlic mixture, adding yeast in a predetermined ratio to the garlic mixture and leaving it to stand for a period of time for fermentation to obtain a garlic fermentation broth, performing cryogenic distillation on the garlic fermentation broth to obtain a garlic extract, and adding a cleaning agent in a predetermined ratio to the garlic extract for mixture to obtain the human body cleaner. The present invention uses the herbal human body cleaner made from garlic to clean human body and reduce symptoms of dandruff. Moreover, long-term use of the present invention will not cause either antibiotic resistance or environmental degradation.

Abstract: An aqueous based formulation for a personal care product, that relies upon the use of fulvic-humic acid and/or humic acid, which acid(s) are present at a level of 0.01 wt. % to 10.0 wt. % and activated carbon black at a level of ?5.0 wt. %.

Abstract: Disclosed is a method of treating a fine line or wrinkle in a person's skin. The method includes topically applying to the fine line or wrinkle a composition comprising an effective amount of Commiphora mukul resin or an extract thereof that includes oleo gum resin. Topical application of the composition to the fine line or wrinkle reduces the appearance of the fine line or wrinkle.

Abstract: The present invention relates to an antioxidant composition for the skin. More specifically, it relates to an antioxidant composition for the skin having: Saccharomyces ferment; and 60 -ketoglutaric acid or niacinamide alone or a mixture thereof. The antioxidant composition for the skin according to the present invention has not only an excellent antioxidant effect but also a high long lasting effect. Therefore, it provides an enhanced antioxidant effect when applied to the skin and it enables manufacture of various products such as cosmetics and medicines because it is not harmful to the human body.

Abstract: Shellac is used as a thermal protectant to protect hair from damage by the heat generated from styling tools such as flat irons, curling irons, curling brushes, blow dryers and the like.

Abstract: The invention provides pharmaceutical compositions for the treatment of neoplastic diseases, fluke infestations and Lyme disease, comprising compounds capable of providing dihydroartemesinin and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.

Abstract: The present application is directed to transdermal formulations for the delivery of celecoxib to a subject for the treatment of celecoxib-responsive diseases or conditions. In particular, the transdermal formulation is an emulsion comprising an oil phase, an aqueous phase and an external phase.

Abstract: Aspects of the invention relate to topical and ocular formulations of spherical nucleic acids (SNA), as well as methods of use thereof and compositions thereof.

Abstract: A method comprising: administering an effective amount of a topical dipyridamole to a subject in need thereof due to a disorder selected from the group consisting of keratitis, corneal abrasion and corneal ulcer.

Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

Abstract: A package, system and methods allow for custody and control of drugs, especially for an abuse-prone drug. A package for custody and control of a dose of an active agent, includes a unit dose of an active agent, and an individual package sealing the unit dose therein, the package having a custody and control product identifier unique to each unit dose provided on the package. A system for custody and control of a dose of an active agent, includes an individual package of one unit dose of an active agent, the package having a custody and control product identifier unique to each unit dose provided on the package, and a database containing data reflecting the custody and control identifier corresponding to each unit dose and an identifier configured to be able to identify the party to whom each unit dose is provided.

Abstract: A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well.

Abstract: Described herein are nucleic acid based nanoparticles that can contain a cargo molecule. The nanoparticles described herein can be used to deliver a cargo molecule to a cell or area of interest.

Abstract: The present invention relates to a composition comprising a mixture of Saccharomyces boulardii cells and of a wax.

Abstract: The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.

Abstract: This document relates to an aqueous composition comprising chlorambucil and human serum albumin, wherein the chlorambucil and the human serum albumin in the aqueous composition have a ratio by weight from about 1:10 to about 1:2000, wherein the aqueous composition comprises at least one water-miscible organic solvent. This document also relates to a solid composition comprising chlorambucil and human serum albumin. This document also relates to a liquid pharmaceutical composition comprising the solid composition comprising the chlorambucil and the human serum albumin, and a pharmaceutically acceptable carrier.

Abstract: The present invention discloses a sanguisorbigenin polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 30 parts of sanguisorbigenin and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of sanguisorbigenin polymer micelle prepared is the best, and using other materials can lead to the lowered preparation quality. In pharmacodynamic experiment, compared with the model group, the sanguisorbigenin micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug of sanguisorbigenin, indicating the sanguisorbigenin polymer micelle has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug of sanguisorbigenin.

Abstract: A pharmaceutical solution for a medication delivery apparatus, especially a metered dose inhaler, is described. The pharmaceutical solution comprises: (a) a liquefied propellant component consisting essentially of and preferably consisting entirely of 1,1-difluoroethane (R-152a); (b) ethanol; and (c) a drug component dissolved in the propellant/ethanol mixture consisting of at least one drug selected from the group consisting of beclomethasone dipropionate (BDP) and fluticasone propionate (FP).

Abstract: The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.

Abstract: Nanolipoprotein particles having at least a scaffold protein component and a membrane lipid component and related compositions, methods and systems are described. The membrane lipid component includes at least one or more membrane forming lipids, one or more polymerized lipids and/or one or more polymerizable lipids.

Abstract: A method of preparing a pharmaceutical microsphere, the method including: adding a silica microsphere to an acid, stirring, adding an alkali to neutralize the acid until the pH value of the mixture of the acid and the alkali is 6-7, filtering and collecting a resulting product, washing, drying, and sieving, to yield a pharmaceutical microsphere. Also provided is a method of preparing a pharmaceutical preparation includes coating the pharmaceutical microsphere with an isolation layer, a taste-masking layer, a sustained-release layer, or a combination thereof.

Abstract: A method for manufacturing a preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent elution properties, preferable hardness and high drug content uniformity, and a premix drug substance of acetaminophen which has improved manufacturability. According to the method in which acetaminophen having a preset particle size is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed and manufacturing efficiency can be elevated. Thus, this method is highly useful for manufacturing an acetaminophen preparation having improved administrability, for example, a reduced size.

Abstract: A stable tablet-in-tablet pharmaceutical composition having fixed dose combinations of cyclophosphamide and capecitabine and one or more pharmaceutically acceptable excipient. As disclosed is a process for the preparation thereof, and a method their use in treating cancer diseases.

Abstract: The disclosure provides for improved pharmaceutical compositions containing an active pharmaceutical ingredient and a non-polymeric lubricant and methods of manufacturing the same. In particular, the compositions are prepared using thermal processing or solvent spraying and provide improved properties as well as more efficient methods of manufacture.

Abstract: The invention relates to a tamper-resistant pharmaceutical dosage form comprising one or more particles, wherein each of said one or more particles comprises a pharmacologically active ingredient and a physiologically acceptable polymer; has a breaking strength of at least 300 N; has a weight of at least 2 mg; and optionally, comprises a film-coating; wherein the total weight of the pharmaceutical dosage form is greater than the total weight of said one or more particles.

Abstract: Methods for inhibiting tissue ossification or calcification in a subject, comprising administering a therapeutically effective amount of BMP I inhibitor-loaded microparticles to a subject in need thereof, wherein the administration provides local and sustained release of the BMP I inhibitor thereby inhibiting tissue ossification or calcification.

Abstract: The present invention relates to a pharmaceutical composition comprising Levetiracetam, Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation.

Abstract: A device for delivery of a first therapeutic agent and a second therapeutic agent to a site in epithelial tissue includes a first layer having a first, freeze-dried polymeric matrix having first and second opposed surfaces, formed by a composition including chitosan, a hydration promoter, a particle adhesion inhibitor, and a particle aggregation inhibitor, and a plurality of first particles embedded within the first matrix so as to be directly surrounded by, and in contact with, the first matrix, the first particles containing the first therapeutic agent and having a coating around the first therapeutic agent, the coating including chitosan. The device further includes a second layer, adjacent to the first layer, having a second, freeze-dried polymeric matrix containing the second therapeutic agent, the first layer and/or the second layer is configured to be attached to the site in the epithelial tissue.

Abstract: The invention provides an agent delivery system comprising an agent preparation encapsulated within a membrane composition. The invention further provides a membrane composition comprising a ganglioside and lipid for encapsulating agents, and processes for preparing the membrane compositions. The invention further provides agent preparations encapsulated within the membrane compositions, including a plurality of individual particles wherein each particle contains agent preparation individually encapsulated within membrane composition. The invention also provides processes for preparing encapsulated agent preparations or individual particles of encapsulated agent preparations. The agents may be biologically active including hydrophilic, hydrophobic, small molecule or large molecule therapeutic agents. The invention further provides pharmaceutical compositions comprising encapsulated agent preparations or individual particles of encapsulated agent preparations.

Abstract: The present invention relates to a method for producing articles impregnated with at least one plant substance from at least one plant, characterized in that it comprises the following steps: a) Extraction and/or pressing of at least one plant (V1), or at least one part of said plant, producing a liquid plant extract (E1) and a solid fibrous residue (R1), then b) Separation of said plant extract (E1) from said fibrous residue (R1), and c) Destructuring of said fibrous residue (R1), d) Production of a fibrous web or of an article made from the fibrous residue (R1) obtained in step c), and e) Impregnation of said fibrous residue (R1) with (i) at least said plant extract (E1), which is optionally concentrated, purified, flavored and/or fragranced, with (ii) at least one water-soluble or liposoluble plant substance isolated from said plant extract (E1), with (iii) at least one composition comprising at least one optionally concentrated, purified, flavored and/or fragranced water-soluble or liposoluble substanc

Abstract: A hydrophilic active molecule delivery system whereby active molecules can be released on demand and/or a variety of different active molecules can be delivered from the same system and/or different concentrations of active molecules can be delivered from the same system. The system may be used to deliver/release hydrophilic active ingredients, generally.

Abstract: The present application relates to methods and uses of CB2 target agent local anaesthetics such as beta-caryophyllene for treatment of interstitial cystitis in a subject, optionally together with the administration or use of an additional agent for treating interstitial cystitis such as dimethyl sulfoxide (DMSO) or methylsulfonylmethane (MSM).

Abstract: A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodege

Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.

Abstract: Dosage forms, drug delivery systems, methods related to sustained release of dextromethorphan or improved therapeutic effects. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.

Abstract: The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.

Abstract: The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.

Abstract: The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.

Abstract: The present invention provides methods of ameliorating or reducing the extent of cardiac arrhythmia disorders, by administering an inhibitor of histone deacetylase enzyme (HDAC).

Abstract: The present disclosure relates to methods for the treatment of sarcoidosis. In certain aspects and embodiments, the disclosure provides compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof and/or the use of such compositions for the treatment of Sarcoidosis. In another aspect, the disclosure relates to compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof plus a second active agent. In yet another aspect, the disclosure relates to kits containing agents useful for the treatment of sarcoidosis.

Abstract: The present invention relates to methods of treating certain activated skin disorders in a subject comprising administering to the subject an effective amount of an agent that can reduce energy metabolism. An agent reduces energy metabolism may be administered topically as a dermatological product such as gels, creams, ointments, foams, patches or others.